Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 11884598
Fang X, et al. (2002) Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 22, 2099-110 11884598
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S21-p - GSK3A (human)
Modsite: sGrARtssFAEPGGG SwissProt Entrez-Gene
Orthologous residues
GSK3A (human): S21‑p, GSK3A (mouse): S21‑p, GSK3A (rat): S21‑p, GSK3A (cow): S21‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293T (epithelial), Swiss 3T3 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE PKCD (human)
KINASE PKCA (human)
KINASE PKCG (human)
KINASE PKCH (human)
KINASE PKCB iso2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCA (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme
KINASE PKCH (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme
KINASE PKCB (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme

S9-p - GSK3B (human)
Modsite: SGRPRttsFAEsCkP SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S9‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293T (epithelial), Swiss 3T3 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE PKCA (human)
KINASE PKCD (human)
KINASE PKCG (human)
KINASE PKCH (human)
KINASE PKCB iso2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCH (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme
KINASE PKCB (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme
KINASE PKCA (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPA no change compared to control
LPA LPAR1 (human) no effect upon treatment-induced increase
LPA EDG4 (human) increase
LPA EDG7 (human) increase

Y1021-p - PDGFRB (human)
Modsite: PNEGDNDyIIPLPDP SwissProt Entrez-Gene
Orthologous residues
PDGFRB (human): Y1021‑p, PDGFRB (mouse): Y1020‑p, PDGFRB (rat): Y1020‑p
Characterization
Methods used to characterize site in vivo mutation of modification site
Relevant cell lines - cell types - tissues:  293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Downstream Regulation
Effect of modification (function):  phosphorylation
Comments:  AKT and GSK3 phosphorylation

T308-p - Akt1 (mouse)
Modsite: KDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293T (epithelial), Swiss 3T3 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPA increase
wortmannin LPA inhibit treatment-induced increase
LY294002 LPA inhibit treatment-induced increase
insulin increase
wortmannin insulin inhibit treatment-induced increase
LY294002 insulin inhibit treatment-induced increase

S21-p - GSK3A (mouse)
Modsite: sGRARtssFAEPGGG SwissProt Entrez-Gene
Orthologous residues
GSK3A (human): S21‑p, GSK3A (mouse): S21‑p, GSK3A (rat): S21‑p, GSK3A (cow): S21‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293T (epithelial), Swiss 3T3 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCH (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme
KINASE PKCB (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme
KINASE PKCA (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPA increase
wortmannin LPA no effect upon treatment-induced increase
LY294002 LPA no effect upon treatment-induced increase
Ro31-8220 LPA inhibit treatment-induced increase
GF109203X LPA inhibit treatment-induced increase
insulin increase
wortmannin insulin inhibit treatment-induced increase
LY294002 insulin inhibit treatment-induced increase
Ro31-8220 insulin no effect upon treatment-induced increase
GF109203X insulin no effect upon treatment-induced increase
IGF-1 increase
Ro31-8220 IGF-1 no effect upon treatment-induced increase
PDGF increase
Ro31-8220 PDGF no effect upon treatment-induced increase
phorbol_ester increase
Ro31-8220 phorbol_ester inhibit treatment-induced increase
GF109203X phorbol_ester inhibit treatment-induced increase

S9-p - GSK3B (mouse)
Modsite: SGRPRttsFAEsCKP SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S9‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293T (epithelial), Swiss 3T3 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCH (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme
KINASE PKCA (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme
KINASE PKCB (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPA increase
wortmannin LPA no effect upon treatment-induced increase
LY294002 LPA no effect upon treatment-induced increase
Ro31-8220 LPA inhibit treatment-induced increase
GF109203X LPA inhibit treatment-induced increase
insulin increase
wortmannin insulin inhibit treatment-induced increase
LY294002 insulin inhibit treatment-induced increase
Ro31-8220 insulin no effect upon treatment-induced increase
GF109203X insulin no effect upon treatment-induced increase
IGF-1 increase
Ro31-8220 IGF-1 no effect upon treatment-induced increase
PDGF increase
Ro31-8220 PDGF no effect upon treatment-induced increase
phorbol_ester increase
Ro31-8220 phorbol_ester inhibit treatment-induced increase
GF109203X phorbol_ester inhibit treatment-induced increase